OXFORD, UK – 16 January 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a US$3.3 million contract from the US Defense Threat Reduction Agency (DTRA) to develop biodefence vaccine adjuvants using the company’s proprietary PolyMAP technology to help improve the safety and efficacy of two vaccines candidates:
Mercia Growth Fund SEIS investment opportunity closed within three months Birmingham, 19 November 2012. Mercia Fund Management (MFM) today announced an over subscription to the SEIS portion of its Mercia Growth Fund, less than three months after the fund’s launch. The Mercia Growth Fund, a ‘hybrid’ fund offering both Seed EIS (SEIS) and later stage
SALT LAKE CITY, Utah, 2012-11-12 – Allinea Software shifted the performance landscape at SC12 today with the announcement of a new performance analysis tool, Allinea MAP. Better known for their high-performance, scalable parallel debugger, Allinea DDT, the company has taken an unusual tack in developing the new product. “We worked with a range of leading
Mercia Fund Management has been in the spotlight in the UK press recently with articles in the Financial Times and The Sunday Times. In an article in The Sunday Times on 30 September 2012, “Spotlight on tax saving schemes”, Mercia Fund Management’s Growth Fund was highlighted as a good example for tax efficient saving. “Mercia
Investors gain update on Venture Capital Trusts, Enterprise Investment Schemes and hybrid EIS/SEIS funds Birmingham, 6 November 2012. Mercia Fund Management (MFM) will be presenting its Mercia Growth Fund, a ‘hybrid’ fund offering combining separate Seed EIS (SEIS) and later stage EIS investments, at the VCT and EIS Investor Forum on 21 November 2012. Attended
FOR IMMEDIATE RELEASE‘OCTAVE’ Study Will AssessColoAd1in Patients with Ovarian Cancer OXFORD, UK – 31 October 2012– PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1
North Brunswick, NJ and London, UK – 23 October 2012. Biotecnol, Inc. and PolyTherics Ltd. have entered into a collaboration for the development of multi-specific Tribody Drug Conjugates (TDCs). The companies will combine Biotecnol’s Tribody technology with PolyTherics’ proprietary site-specific linker technologies to attach cytotoxic payloads to various Tribodies for targeted cancer therapy. Tribody molecules
Ideas of the future get a chance to blossom with multi million pound investment fund Bright ideas emerging from universities in the West Midlands now have the chance to become reality with the continued support of the vital Mercia Fund 1. Over the next 3 years, innovative technology ideas that have been developing quietly through
London, UK, 15 th October 2012 – PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, has extended its collaboration with a top five pharmaceutical company to further investigate applications of PolyTherics’ polymer, PolyPEG®. PolyPEG™ is a patented polymer designed to extend the half-life in the body of therapeutic proteins
Mark Payton, managing director of Mercia Fund Management, talks university spin- outs and looks at successful companies from the University of Warwick.Working with eight Midlands’ universities, Mercia Fund Management has supported spin- outs from seed to successful exit through investment, sourcing the right people to manage the funded company, and providing strategic input. This article